lamifiban has been researched along with Recrudescence in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moliterno, DJ; Steinhubl, SR | 1 |
| Rossi, G | 1 |
| Greenbaum, AB; Harrington, RA; Hudson, MP; Ohman, EM | 1 |
| Califf, RM; Lincoff, AM; Topol, EJ | 1 |
| Berkowitz, SD | 1 |
4 review(s) available for lamifiban and Recrudescence
| Article | Year |
|---|---|
Glycoprotein IIb/IIIa receptor antagonists for the treatment of unstable angina.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clinical Trials as Topic; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Tirofiban; Treatment Outcome; Tyrosine | 1997 |
Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction.
Topics: Abciximab; Acetates; Animals; Antibodies, Monoclonal; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dogs; Double-Blind Method; Drug Evaluation, Preclinical; Drug Therapy, Combination; Eptifibatide; Fibrinogen; Fibrinolytic Agents; Forecasting; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Pilot Projects; Plasminogen Activators; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome; Tyrosine | 1999 |
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
Topics: Abciximab; Acetates; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Combined Modality Therapy; Coronary Disease; Drug Monitoring; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Myocardial Infarction; Patient Selection; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Recurrence; Risk Factors; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Coronary Artery Bypass; Coronary Disease; Drug Approval; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Mice; Multicenter Studies as Topic; Myocardial Ischemia; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Recurrence; Safety; Single-Blind Method; Stents; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine; United States; United States Food and Drug Administration | 2000 |
1 other study(ies) available for lamifiban and Recrudescence
| Article | Year |
|---|---|
[Superaspirin in the platelet aggregation inhibitor therapy].
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Aspirin; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Integrins; Myocardial Infarction; Oligopeptides; Peptides, Cyclic; Platelet Aggregation Inhibitors; Recurrence; Sulfoxides; Thiazolidines; Time Factors; Tyrosine | 1997 |